Sugi Predict

Sugi Predict / Targets / NCAPD2

NCAPD2

Condensin complex subunit 1 · Q15021 · NCAPD2 on Sugi Atlas →

0 patent compounds predicted against NCAPD2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to NCAPD2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Breakpoint Analysis of de Novo Apparently Balanced Chromosomal Translocations EARLY_PHASE1COMPLETED
Identification of Genetic Basis of Atrioventricular Conduction Defects: From Congenital Forms to Degenerative Forms nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk nanNOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Genetic Studies of Strabismus, Congenital Cranial Dysinnervation Disorders (CCDDs), and Their Associated Anomalies nanRECRUITING
Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis. nanCOMPLETED
Role of the Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections nanCOMPLETED
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 nanCOMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
MD2, Cystatin C and DNA Methylation Tags as Serum Biomarkers for POCD. nanUNKNOWN
Corpus Callosum Agenesis and Intellectual Disability nanCOMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders nanCOMPLETED
The Contribution of Optical Mapping to the Characterization of Chromosomal Rearrangements in Patients With Neurodevelopmental Disorders nanRECRUITING
Genetics and Psychopathology in the 22q11 Deletion Syndrome nanUNKNOWN
PCD New Gene Discovery nanCOMPLETED
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy nanNOT_YET_RECRUITING
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease nanRECRUITING
Epidemiological and Genetic Studies of Body Mass Index nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Whole Exome Sequencing in Prenatal Diagnosis of Agenesis of the Corpus Callosum nanCOMPLETED
PCM1-JAK2 in Therapy Related Neoplasms nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a NCAPD2 binder may also engage these)

ProteinNameSimilarity
Q8K2Z4 — 1.000 Q8K2Z4 →
O70576 — 0.994 O70576 →
Q99M76 — 0.991 Q99M76 →
Q9YHY6 — 0.990 Q9YHY6 →
Q9UJ98 — 0.989 Q9UJ98 →
Q8C3S2 — 0.989 Q8C3S2 →
B0I564 — 0.989 B0I564 →
Q7TPV4 — 0.988 Q7TPV4 →
Q6DRN3 — 0.987 Q6DRN3 →
Q9C0B7 — 0.987 Q9C0B7 →
MYBBP1A Myb-binding protein 1A 0.986 landscape →
Q8BM55 — 0.986 Q8BM55 →
TTI1 TELO2-interacting protein 1 homolog 0.986 landscape →
Q08CY4 — 0.986 Q08CY4 →
Q8N3U4 — 0.986 Q8N3U4 →
Q0V9L1 — 0.986 Q0V9L1 →
Q9UJY4 — 0.986 Q9UJY4 →
O35821 — 0.985 O35821 →
Q9DC40 — 0.985 Q9DC40 →
Q9YHB5 — 0.985 Q9YHB5 →
E0CZ22 — 0.985 E0CZ22 →
Q9DGN1 — 0.985 Q9DGN1 →
D3Z8X7 — 0.985 D3Z8X7 →
O75800 — 0.985 O75800 →
Q8WVM7 — 0.985 Q8WVM7 →
Q6GPP1 — 0.985 Q6GPP1 →
Q9D3E6 — 0.984 Q9D3E6 →
A1L1L2 — 0.984 A1L1L2 →
Q9UNS1 — 0.984 Q9UNS1 →
FANCI Fanconi anemia group I protein 0.984 landscape →